<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888355</url>
  </required_header>
  <id_info>
    <org_study_id>2009_582</org_study_id>
    <secondary_id>MK0954-065</secondary_id>
    <nct_id>NCT00888355</nct_id>
  </id_info>
  <brief_title>MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Losartan Given Once or Twice Daily in Patients With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The study had a 4 week single blind placebo period followed by 12 weeks of double blind
      treatment. Patients were randomized to one of four treatment arms to evaluate the
      antihypertensive efficacy of Losartan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 1992</start_date>
  <completion_date type="Actual">February 1993</completion_date>
  <primary_completion_date type="Actual">January 1993</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12</measure>
    <time_frame>At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12</measure>
    <time_frame>At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12</measure>
    <time_frame>At baseline and at 12 weeks (6 hours after last morning dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categories of Antihypertensive Response in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12</measure>
    <time_frame>24 hours after last morning dose and 12 hours after last PM dose at 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">428</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 50 q.a.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 25 b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 25 q.a.m.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan potassium</intervention_name>
    <description>losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>MK0954</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo</intervention_name>
    <description>placebo to losartan tablet q.a.m. , for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been diagnosed with mild to moderate hypertension

          -  Patient has no treatment or active medical problem, other than hypertension that might
             affect the patients blood pressure

        Exclusion Criteria:

          -  Pregnant of lactating female patients

          -  Secondary hypertension or history of malignant hypertension

          -  Sitting systolic blood pressure &gt; 210 mmHg

          -  History of stroke

          -  History of myocardial infarction with in the past year

          -  Current of prior history of heart failure

          -  Known hypersensitivity to losartan

          -  Obesity

          -  Patients known to be HIV positive or known to be positive for Hepatitis B

          -  Absence of one kidney

          -  Patient is abusing or previously abused alcohol or drugs with in past two years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <results_first_submitted>May 7, 2009</results_first_submitted>
  <results_first_submitted_qc>May 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2009</results_first_posted>
  <last_update_submitted>July 2, 2009</last_update_submitted>
  <last_update_submitted_qc>July 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck &amp; Co., Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at 37 sites in the United States. Prime Therapy Period: May, 1992 to January1993</recruitment_details>
      <pre_assignment_details>Patients could be randomized if sitting diastolic blood pressure (SiDBP) after 2 and 4 weeks of placebo washout was 95-115 mm Hg and the difference between measurements at the 2 visits did not differ by &gt;7 mm Hg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Losartan placebo orally once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Losartan 25 mg q.d.</title>
          <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Losartan 50 mg q.d.</title>
          <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Losartan 25 mg (b.i.d.)</title>
          <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="106"/>
                <participants group_id="P4" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Losartan placebo orally once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Losartan 25 mg q.d.</title>
          <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Losartan 50 mg q.d.</title>
          <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Losartan 25 mg (b.i.d.)</title>
          <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="106"/>
            <count group_id="B4" value="106"/>
            <count group_id="B5" value="428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="10.6"/>
                    <measurement group_id="B2" value="53.0" spread="10.7"/>
                    <measurement group_id="B3" value="54.0" spread="10.1"/>
                    <measurement group_id="B4" value="52.4" spread="10.1"/>
                    <measurement group_id="B5" value="53.5" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vietnamese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sitting Diastolic Blood Pressure (SiDBP)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.5" spread="5.1"/>
                    <measurement group_id="B2" value="101.8" spread="5.5"/>
                    <measurement group_id="B3" value="102.4" spread="6.4"/>
                    <measurement group_id="B4" value="102.0" spread="5.3"/>
                    <measurement group_id="B5" value="101.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12</title>
        <description>Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiDBP at Week 12</description>
        <time_frame>At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)</time_frame>
        <population>The primary analysis employed an &quot;all patients treated&quot; approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12</title>
          <description>Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiDBP at Week 12</description>
          <population>The primary analysis employed an &quot;all patients treated&quot; approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="8.4"/>
                    <measurement group_id="O2" value="-5.8" spread="6.7"/>
                    <measurement group_id="O3" value="-6.3" spread="7.4"/>
                    <measurement group_id="O4" value="-8.0" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12</title>
        <description>Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiSBP at Week 12</description>
        <time_frame>At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)</time_frame>
        <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12</title>
          <description>Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiSBP at Week 12</description>
          <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="15.1"/>
                    <measurement group_id="O2" value="-7.2" spread="13.9"/>
                    <measurement group_id="O3" value="-7.6" spread="12.6"/>
                    <measurement group_id="O4" value="-8.8" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12</title>
        <description>Mean change from baseline in peak (6 hours after the last morning dose) SiDBP at Week 12</description>
        <time_frame>At baseline and at 12 weeks (6 hours after last morning dose)</time_frame>
        <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12</title>
          <description>Mean change from baseline in peak (6 hours after the last morning dose) SiDBP at Week 12</description>
          <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="9.7"/>
                    <measurement group_id="O2" value="-7.7" spread="8.5"/>
                    <measurement group_id="O3" value="-8.7" spread="8.1"/>
                    <measurement group_id="O4" value="-9.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categories of Antihypertensive Response in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12</title>
        <description>Patients with trough SiDBP &lt;90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg or increased were in Category III.</description>
        <time_frame>24 hours after last morning dose and 12 hours after last PM dose at 12 weeks</time_frame>
        <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Categories of Antihypertensive Response in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12</title>
          <description>Patients with trough SiDBP &lt;90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg or increased were in Category III.</description>
          <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Category I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Clinical Adverse Experiences (CAEs)</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinical Adverse Experiences (CAEs)</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Serious CAEs</title>
        <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious CAEs</title>
          <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Drug-related CAEs</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs during the 12-week treatment period</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related CAEs</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs during the 12-week treatment period</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients Discontinued Due to CAEs</title>
        <description>Patients discontinued due to CAEs during the 12-week treatment period</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Discontinued Due to CAEs</title>
          <description>Patients discontinued due to CAEs during the 12-week treatment period</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not discontinued due to CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients Who Died</title>
        <description>Patients who died during the 12-week treatment period</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Died</title>
          <description>Patients who died during the 12-week treatment period</description>
          <population>All patients who took study medication were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Who Died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Laboratory Adverse Experiences (LAEs)</title>
        <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication and had any laboratory tests performed were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Adverse Experiences (LAEs)</title>
          <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>All patients who took study medication and had any laboratory tests performed were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Serious LAEs</title>
        <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication and had any laboratory tests performed were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious LAEs</title>
          <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
          <population>All patients who took study medication and had any laboratory tests performed were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Drug-related LAEs</title>
        <description>Patients with drug-related LAEs during the 12-week treatment period</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication and had any laboratory tests performed were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related LAEs</title>
          <description>Patients with drug-related LAEs during the 12-week treatment period</description>
          <population>All patients who took study medication and had any laboratory tests performed were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients Discontinued Due to LAEs</title>
        <description>Patients discontinued due to LAEs during the 12-week treatment period</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients who took study medication and had any laboratory tests performed were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan placebo orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 25 mg q.d.</title>
            <description>Losartan 25 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 50 mg q.d.</title>
            <description>Losartan 50 mg orally once daily (q.d.) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 25 mg (b.i.d.)</title>
            <description>Losartan 25 mg orally twice daily (b.i.d.) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Discontinued Due to LAEs</title>
          <description>Patients discontinued due to LAEs during the 12-week treatment period</description>
          <population>All patients who took study medication and had any laboratory tests performed were included in the analysis</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued due to LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not discontinued due to LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Note that deaths are not entered under &quot;drop reasons&quot; in the participant flow panel because the patients who died are already counted as dropped due to adverse event.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Executive Vice President, Clinical and Quantitative Sciences</name_or_title>
      <organization>Merck &amp; Co., Inc.</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

